Protein Summary
Plays a central role in the biogenesis of melanosomes. Involved in the maturation of melanosomes from stage I to II. The transition from stage I melanosomes to stage II melanosomes involves an elongation of the vesicle, and the appearance within of distinct fibrillar structures. Release of the soluble form, ME20-S, could protect tumor cells from antibody mediated immunity. This gene encodes a melanocyte-specific type I transmembrane glycoprotein. The encoded protein is enriched in melanosomes, which are the melanin-producing organelles in melanocytes, and plays an essential role in the structural organization of premelanosomes. This protein is involved in generating internal matrix fibers that define the transition from Stage I to Stage II melanosomes. This protein undergoes a complex pattern of prosttranslational processing and modification that is essential to the proper functioning of the protein. A secreted form of this protein that is released by proteolytic ectodomain shedding ma ...more
- ENST00000449260
- ENSP00000402758
- ENSG00000185664
- ENST00000548493
- ENSP00000447374
- ENST00000548747
- ENSP00000448828
- ENST00000550464
- ENSP00000450036
- ENST00000552882
- ENSP00000449690
- D12S53E
- PMEL17
- SILV
- P1
- SI
- SIL
- ME20
- P100
- SILV
- ME20M
- gp100
- ME20-M
- PMEL17
- D12S53E
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
cellular component | 0.96 | ||
histone modification site profile | 0.85 | ||
gene perturbation | 0.83 | ||
biological term | 0.64 | ||
cell line | 0.61 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 926.32 (req: < 5)
Gene RIFs: 62 (req: <= 3)
Antibodies: 1014 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 926.32 (req: >= 5)
Gene RIFs: 62 (req: > 3)
Antibodies: 1014 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 3
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 1